Portfolio Companies News
July 18, 2018BONESUPPORT appoints Michael Diefen...
Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONESUPPORT’s Chief Medical Officer, has been appointed to assume a broader role as Head of R&D, Medical and Clinical ... read more
July 18, 2018Cash position and activity update f...
Solid cash position of €13.5 million at June 30, 2018 Key highlights of H1 2018: primary objective met in the first results of TARGET PHASE II study and with the strategic partnership with the University of North Texas Health Science Center Key perspectives by the end of 20... read more
July 13, 2018HealthCap makes 112th investment as...
Funds to be used to continue the clinical development of sevuparin for sickle cell disease STOCKHOLM, SWEDEN – 13 July 2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has ... read more
July 12, 2018Altimmune Restructures Financing Ag...
GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into agreements with substantially all of the remaining investors in its Series B Financing to ... read more
July 12, 2018Targovax and SOTIO announce first p...
Oslo, Norway, 12 July 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, and SOTIO, a biotechnology company owned by the PPF Group, announce that the first patient has been dosed with ONCOS-102 i... read more
May 02, 2018Q1 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 112 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.